Ranibizumab for Treating Submacular Vascularized Pigment Epithelial Detachments



Status:Archived
Conditions:Cancer, Cardiology, Ocular, Psychiatric
Therapuetic Areas:Cardiology / Vascular Diseases, Oncology, Ophthalmology, Psychiatry / Psychology
Healthy:No
Age Range:Any
Updated:7/1/2011
Start Date:September 2008
End Date:January 2012

Use our guide to learn which trials are right for you!

Trial Summary
Trial Overview
Inclusion Criteria

A Phase I Study to Evaluate the Efficacy and Safety of Treating Subfoveal Pigment Epithelial Detachment Associated With Choroidal Neovascularization With Anti-vascular Endothelial Growth Factor Fragment, Ranibizumab.


This is a multicenter, randomized, open-label study. 40 patients will be followed for a
period of 12 months. All consented and enrolled patients will receive either 0.5mg or 2.0mg
of intravitreal ranibizumab injection.



We found this trial at
3
sites
Juels Stein Eye Institute
Los Angeles, California 90095
?
mi
from
Los Angeles, CA
Click here to add this to my saved trials
Southern California Desert Retina Consultants
Palm Desert, California 92211
?
mi
from
Palm Desert, CA
Click here to add this to my saved trials
Black Hills Eye Institute
Rapid City, South Dakota 57701
?
mi
from
Rapid City, SD
Click here to add this to my saved trials